Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorCentre Hospitalier Régional Metz-Thionville

About this trial

This is an interventional multicenter prospective noninferiority non-randomized double-blind controlled before and after study.

The aim of this study is to demonstrate that standard precautions alone are not inferior to contact precautions by comparing the incidence density of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae acquired in geriatric units before and after discontinuing contact precautions.

Eligibility criteria

Qualifiers

Adult patient (> 65 years old)

Patient hospitalized in geriatrics during the study period

Free and informed consent obtained from the patient (or his trusted person or legal representative) within 48 hours of its admission at the geriatric unit

Patient affiliated to a social security scheme

Disqualifiers

Patient requiring contact precaution for an indication other than ESBL during the patient stay (COVID-19, classical PCC excluding EBLSE, Clostridium difficile PCC, scabies PCC and BHRe PCC)

Patient's stay period less than 4 days

Trial design

Treatments tested in this trial

  • Discontinuation of contact precautions for ESBLE

Treatment groups

954 Participants
are divided into 2 treatment groups